My first reaction is that broad market concerns and tax loss selling has exacerbated market disappointment/ambivalence to the PFS. However given the apparent ample room to improve parameters of the study and therefore economics / NPV, its not a long bow to draw to suggest that the sp has been stretched too low. Like a rubber band it should eventually snap back to the "norm".
The hard thing to judge is what is the norm? Not sure at the moment but a 50% bounce from the "crash range" shouldnt be hard to do which would take her to 50c, Newsflow will drive it from there.. Set your stops at about 20c and the risk reward looks attractive. Its healthy to see volume drop off and tighter trading ranges ensue which can suggest that selling is drying up and could be a trigger for value seeking money to jump in from the sidelines.
Will do some work on her over the weekend then I might start sniffing around the stock early next week before the start of the new FY.
It must be a hard pill to swallow for long termers but hopefully you'll claw some value back in the coming weeks/months.
All IMHO only
Good luck to holders.
- Forums
- ASX - By Stock
- PLV
- current status?
current status?, page-45
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PLV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online